US clears Sysmex' low volume haematology analyser:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared for sale Sysmex America's automated haematology analyser for the low volume clinical setting. The pocH-100i system is a compact complete blood count (CBC) and 3-part differential haematology analyser that provides results comparable to the firm's high-end systems, says the Mundelein, Illinois company, the US headquarters of Japan's Sysmex. It is to be marketed to the clinical laboratories as well as to the physician offices. "The FDA's clearance...paves the way for our company to enter the physician marketplace with a product that has application for the more than 13,000 physician office labs performing non-CLIA waived CBC testing as part of patient care," says Kazuya Obe, Sysmex America's president and CEO.
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.